Eight more surgeons approved to use Allied's CardioCel in adults

Eight surgeons, based at The Prince Charles Hospital in Brisbane, were today approved to use Allied Healthcare’s (ASX: AHZ) CardioCel to repair and treat heart defects in adult patients under the Authorised Prescriber Scheme (APS).

CardioCel is a cardiovascular tissue patch used to repair heart deformities, including repairing and reconstructing heart valves. Its properties make it suitable for use by surgeons as a regenerative cardiac repair tissue.

There are now 14 surgeons in Australia that are authorised to use CardioCel for the repair of heart defects. The latest approval, said Allied CEO Lee Rodne, represents “the first department-wide team of cardiac heart surgeons to gain early access to use CardioCel for treating and repairing heart defects in adult patients”. 

The product is also making movements overseas: in August, CardioCel received CE mark approval in Europe for use in both children and adults. Allied Healthcare has also filed for marketing approval to the US FDA and hopes for a result next year.

Over 60 patients have successfully received the tissue implant since the initial procedure was performed. Rodne said the adult market “has the potential to significantly expand the market and revenue for the company considerably”.

Allied Healthcare shares were trading 6.41% higher at $0.083 as of 3.30 pm on Tuesday.